News of Note—ILiAD Biotechnologies, Emergex and more

newspapers
In this week's news of note, Emergex picked up a universal flu vaccine grant. (Pixabay)

Here is some other vaccine news of note for the week:

> ILiAD Biotechnologies announced that the National Institute for Allergy and Infectious Diseases submitted an Investigational New Drug application to study its next-gen pertussis vaccine. Release

> U.K. biotech Emergex picked up a £979,318 ($1.32 million) grant from Innovate UK to advance universal flu vaccine work. Release

> The former chief scientific officer of Moderna's vaccine division, Giuseppe Ciaramella, joined CRISPR startup Beam Therapeutics. Chemical & Engineering News article

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.